Current Hematologic Malignancy Reports最新文献_第9页

MRD in ALL: Optimization and Innovations ALL中的MRD：优化与创新

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-05-26 DOI: 10.1007/s11899-022-00664-6

E. Pierce, B. Mautner, J. Mort, Anastassia Blewett, A. Morris, M. Keng, F. El Chaer

引用次数: 3

Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders 端粒生物学障碍背景下的克隆性造血和骨髓瘤

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-05-07 DOI: 10.1007/s11899-022-00662-8

A. Ferrer, A. Mangaonkar, M. Patnaik

引用次数: 11

Targeting Apoptosis in ALL ALL靶向细胞凋亡

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-04-01 DOI: 10.1007/s11899-022-00661-9

Wesley M. Smith, Daniel R. Reed

引用次数: 0

Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia. 儿童、青少年和青年急性淋巴细胞白血病的长期护理面临的挑战。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2021-11-04 DOI: 10.1007/s11899-021-00657-x

Michael G Douvas, Lara L Riegler

{"title":"Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia.","authors":"Michael G Douvas, Lara L Riegler","doi":"10.1007/s11899-021-00657-x","DOIUrl":"https://doi.org/10.1007/s11899-021-00657-x","url":null,"abstract":"Purpose of review: To discuss the long-term view of treating and following pediatric, adolescent, and young adult patients with acute lymphoblastic leukemia (ALL) - with review of what can be done to prevent, monitor for, and treat complications of therapy.Recent findings: Pediatric, adolescent, and young adult oncology patients, including those with ALL, are living longer with higher overall survival rates as treatments and supportive care for these patients continue to improve. These patients are burdened by the risk of significant health and quality of life consequences as a result of their treatment.. For these patients, the late effects of treatment can be life-threatening, such as secondary cancers or cardiotoxicity, or life-altering with respect to quality of life. The goal of this paper is to review the current literature, research, and surveillance guidelines regarding the late effects of ALL therapy, to outline what can be done to mitigate the toxic effects of oncology treatment, and to extend life expectancy and improve quality of life for our patients. We review risk factors and interventions available to prevent and treat cardiovascular disease, secondary malignancies, endocrine complications (obesity, osteoporosis, infertility, and premature menopause), cognitive effects, and effects on functioning and mortality.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"15-24"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39590768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myeloproliferative Neoplasms with Monocytosis. 骨髓增生性肿瘤伴单核细胞增多症。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2021-11-13 DOI: 10.1007/s11899-021-00660-2

Erika Morsia, Naseema Gangat

{"title":"Myeloproliferative Neoplasms with Monocytosis.","authors":"Erika Morsia, Naseema Gangat","doi":"10.1007/s11899-021-00660-2","DOIUrl":"https://doi.org/10.1007/s11899-021-00660-2","url":null,"abstract":"Purpose of review: Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) that share driver mutations (JAK2/CALR/MPL) resulting in constitutive activation of JAK/STAT and other signaling pathways. Patients with MPN have shortened survival and an inherent risk for leukemic evolution. Prognostically relevant clinical and genetic parameters have been incorporated into mutation-enhanced scoring systems (MIPSS70-plus version 2.0, MIPSS-ET/PV). In the current review, we describe clinical and pathological features along with prognostic significance of MPN with monocytosis.Recent findings: Monocytosis, defined by an absolute monocyte count (AMC) ≥ 1 × 10 9/L, is a typical manifestation of chronic myelomonocytic leukemia (CMML) but is also associated with 21% and 17% of PV and PMF patients, respectively. Recent studies on the subject have reported that MPN patients with monocytosis are older and present with concomitant leukocytosis. In regard to PV, patients with monocytosis harbor unfavorable cytogenetic abnormalities including +8, 7/7q, i(17q), 5/5q-,12p-, inv(3), or 11q23 rearrangement and SRSF2 mutations, whereas PMF patients with monocytosis had significant thrombocytopenia, higher circulating blasts, higher symptom burden, and ASXL1 mutations. Moreover, presence of monocytosis predicted inferior survival in both PV and PMF. Monocytosis in MPN is associated with a distinct clinical and genetic profile and may serve as a marker of aggressive disease biology.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"46-51"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39620135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia. 小儿急性淋巴细胞白血病中中枢神经系统疾病的治疗。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2022-01-13 DOI: 10.1007/s11899-021-00640-6

Jennifer L McNeer, Kjeld Schmiegelow

{"title":"Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia.","authors":"Jennifer L McNeer, Kjeld Schmiegelow","doi":"10.1007/s11899-021-00640-6","DOIUrl":"https://doi.org/10.1007/s11899-021-00640-6","url":null,"abstract":"Purpose of review: The treatment of acute lymphoblastic leukemia (ALL) is one of the success stories of pediatric oncology, but challenges and questions remain, including the optimal approach to the treatment of central nervous system (CNS) leukemia. It is unclear why some children with ALL develop CNS leukemia and others do not, and there remains debate regarding optimal regimens for prophylaxis, upfront treatment, and the treatment of CNS relapses. These topics are especially important since both cranial radiation therapy (CRT) and intensive intrathecal therapy carry risks of both short- and long-term adverse effects. In this review, we aim to identify areas of ongoing debate on this topic, review the biology of CNS leukemia, and summarize clinical trial data that address some of these questions.Recent findings: Both retrospective and meta-analyses have demonstrated that few patients with ALL benefit from CRT as a component of CNS-directed treatment for de novo disease, allowing cooperative groups to greatly limit the number of patients undergoing CRT as part of their initial ALL regimens. More recent efforts are focusing on how best to assay for low levels of CNS disease at the time of diagnosis, as well as the biological drivers that may result in CNS leukemia in certain patients. Progress remains to be made in the identification and treatment of CNS leukemia in pediatric ALL. Advancements have occurred to limit the number of children undergoing CRT, but much has yet to be learned to better understand the biology of and risk factors for CNS leukemia, and novel approaches are required to approach CNS relapse of ALL.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"1-14"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39678956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies. 靶向治疗时代复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的治疗

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2022-01-13 DOI: 10.1007/s11899-021-00652-2

Michael Rainone, Tanya Siddiqi

{"title":"Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.","authors":"Michael Rainone, Tanya Siddiqi","doi":"10.1007/s11899-021-00652-2","DOIUrl":"https://doi.org/10.1007/s11899-021-00652-2","url":null,"abstract":"Purpose of review: The treatment landscape for relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has changed substantially over the past decade and continues to evolve. Despite the emergence of targeted therapies that are well tolerated and prolong survival, the disease remains incurable and relapse is common particularly in individuals with high-risk features. Herein, we review the key literature about the current options for relapsed disease and explore the emerging role of cellular therapies.Recent findings: Clinical trials have established the role of Bruton tyrosine kinase inhibitors, selective BCL-2 inhibition, and anti-CD20 monoclonal antibodies as treatment options for CLL/SLL. The role of chimeric antigen receptor T cells has shown promise in individuals with CLL/SLL in early phase clinical trials. Novel therapeutic approaches with targeted therapies have redefined the management of CLL/SLL in both the front-line and relapsed/refractory settings. Optimal management in terms of sequencing or combining therapies, especially in individuals with high-risk features, remains a challenge. The emerging role of cellular therapies has the potential to build upon and further improve the current treatment paradigm.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"39-45"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39819903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities. 远程医疗在血液恶性肿瘤患者护理中的应用:挑战与机遇。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2022-01-11 DOI: 10.1007/s11899-021-00642-4

Jennifer Lloyd, Catherine J Lee

{"title":"Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities.","authors":"Jennifer Lloyd, Catherine J Lee","doi":"10.1007/s11899-021-00642-4","DOIUrl":"https://doi.org/10.1007/s11899-021-00642-4","url":null,"abstract":"Purpose of review: For nearly 20 years, oncology specialty practices have been working to integrate telemedicine technologies into standard patient care models. However, hematology practices have been slower to adopt telemedicine due to traditional care models that rely on interdisciplinary regional care centers and their ability to provide comprehensive and centralized services. Patients have traditionally been able to access high-quality medical care, diagnostics, supportive care, and clinical trials from these regional care centers, but they are required to attend frequent in-person visits to access these services. Rural and underserved patients experience more barriers than their urban counterparts to access the same level of care.Recent findings: The COVID-19 pandemic has elevated telemedicine into the forefront of care, highlighting both promise and limitations to incorporating telemedicine into specialty hematology care. Hematologists should consider the benefits of incorporating telemedicine technologies into standard-of-care practices to promote patient-centered care and provide equal access to all patient populations.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 1","pages":"25-30"},"PeriodicalIF":2.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39671822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Multidisciplinary Approach to Older Adults with Hematologic Malignancies-a Paradigm Shift. 多学科方法治疗老年血液恶性肿瘤-一个范式转变。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2022-02-01 Epub Date: 2022-01-13 DOI: 10.1007/s11899-021-00646-0

Sarah A Wall, Erin Stevens, Jennifer Vaughn, Naresh Bumma, Ashley E Rosko, Uma Borate

引用次数: 2

Future Directions in Chronic Phase CML Treatment. 慢性期CML治疗的未来方向。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-12-01 DOI: 10.1007/s11899-021-00658-w

Nathalie Javidi-Sharifi, Gabriela Hobbs

{"title":"Future Directions in Chronic Phase CML Treatment.","authors":"Nathalie Javidi-Sharifi, Gabriela Hobbs","doi":"10.1007/s11899-021-00658-w","DOIUrl":"https://doi.org/10.1007/s11899-021-00658-w","url":null,"abstract":"Purpose of review: This review will focus on recent and emerging treatment paradigms in chronic phase CML. The discussion of each novel treatment or drug combination will include a brief overview of scientific rational and pre-clinical data, followed by recently published or ongoing clinical trial efforts. The review will be divided into three focus areas in CML treatment: new frontline approaches and approaches to deepen remission, second treatment-free remission studies, and the treatment of refractory disease.Recent findings: The section on new frontline approaches will highlight several strategies of combination therapy. These can be grouped into immunomodulatory approaches with interferons and immune checkpoint inhibitors, targeting of leukemia stem cells with compounds such as venetoclax and pioglitazone, and BCR-ABL1-intrinsic combination therapy with asciminib. The chance at a second treatment-free remission is an important emerging clinical trial concept, and again combination approaches are under investigation. Lastly, in advanced disease, the development of novel tyrosine kinase inhibitors remains a major focus. This review will provide an overview and perspective of treatment strategies on the horizon for chronic phase CML. Despite the already excellent clinical outcomes for most patients, challenges remain with regard to deepening initial responses, prolonging treatment-free remission, and providing efficacious and tolerable options for patients with refractory disease and resistance mutations.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 6","pages":"500-508"},"PeriodicalIF":2.9,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9482097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8